|
Dexcom Inc
g4 platinum system ![]() G4 Platinum System, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/g4 platinum system/product/Dexcom Inc Average 90 stars, based on 1 article reviews
g4 platinum system - by Bioz Stars,
2026-05
90/100 stars
|
Buy from Supplier |
|
Dexcom Inc
cgm system dexcom g4 platinum ![]() Cgm System Dexcom G4 Platinum, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/cgm system dexcom g4 platinum/product/Dexcom Inc Average 90 stars, based on 1 article reviews
cgm system dexcom g4 platinum - by Bioz Stars,
2026-05
90/100 stars
|
Buy from Supplier |
|
Dexcom Inc
g4 platinum transmitters ![]() G4 Platinum Transmitters, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/g4 platinum transmitters/product/Dexcom Inc Average 90 stars, based on 1 article reviews
g4 platinum transmitters - by Bioz Stars,
2026-05
90/100 stars
|
Buy from Supplier |
|
Dexcom Inc
g4 platinum receiver ![]() G4 Platinum Receiver, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/g4 platinum receiver/product/Dexcom Inc Average 90 stars, based on 1 article reviews
g4 platinum receiver - by Bioz Stars,
2026-05
90/100 stars
|
Buy from Supplier |
|
Dexcom Inc
standalone cgm plus multiple injections g4 platinum ![]() Standalone Cgm Plus Multiple Injections G4 Platinum, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/standalone cgm plus multiple injections g4 platinum/product/Dexcom Inc Average 90 stars, based on 1 article reviews
standalone cgm plus multiple injections g4 platinum - by Bioz Stars,
2026-05
90/100 stars
|
Buy from Supplier |
|
Dexcom Inc
dexcom g4 ![]() Dexcom G4, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/dexcom g4/product/Dexcom Inc Average 90 stars, based on 1 article reviews
dexcom g4 - by Bioz Stars,
2026-05
90/100 stars
|
Buy from Supplier |
|
Dexcom Inc
g4 stand-alone system ![]() G4 Stand Alone System, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/g4 stand-alone system/product/Dexcom Inc Average 90 stars, based on 1 article reviews
g4 stand-alone system - by Bioz Stars,
2026-05
90/100 stars
|
Buy from Supplier |
|
Dexcom Inc
dexcom g4 sensor ![]() Dexcom G4 Sensor, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/dexcom g4 sensor/product/Dexcom Inc Average 90 stars, based on 1 article reviews
dexcom g4 sensor - by Bioz Stars,
2026-05
90/100 stars
|
Buy from Supplier |
|
Dexcom Inc
dexcom g4 receiver ![]() Dexcom G4 Receiver, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/dexcom g4 receiver/product/Dexcom Inc Average 90 stars, based on 1 article reviews
dexcom g4 receiver - by Bioz Stars,
2026-05
90/100 stars
|
Buy from Supplier |
|
Dexcom Inc
continuous glucose monitoring systems ![]() Continuous Glucose Monitoring Systems, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/continuous glucose monitoring systems/product/Dexcom Inc Average 90 stars, based on 1 article reviews
continuous glucose monitoring systems - by Bioz Stars,
2026-05
90/100 stars
|
Buy from Supplier |
|
Dexcom Inc
platinum g4/g5 sensor with g4 platinum transmitter ![]() Platinum G4/G5 Sensor With G4 Platinum Transmitter, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/platinum g4/g5 sensor with g4 platinum transmitter/product/Dexcom Inc Average 90 stars, based on 1 article reviews
platinum g4/g5 sensor with g4 platinum transmitter - by Bioz Stars,
2026-05
90/100 stars
|
Buy from Supplier |
|
Dexcom Inc
dexcom software ![]() Dexcom Software, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/dexcom software/product/Dexcom Inc Average 90 stars, based on 1 article reviews
dexcom software - by Bioz Stars,
2026-05
90/100 stars
|
Buy from Supplier |
Image Search Results
Journal: Journal of Diabetes Science and Technology
Article Title: Performance Evaluation of a Continuous Glucose Monitoring System under Conditions Similar to Daily Life
doi:
Figure Lengend Snippet: Mean Absolute Relative Difference and Precision Absolute Relative Difference of the Dexcom G4 CGM System (Mean ± Standard Deviation) a
Article Snippet: According to the local distributor, the Dexcom G4 stand-alone system is identical to the
Techniques: Standard Deviation
Journal: Journal of Diabetes Science and Technology
Article Title: Performance Evaluation of a Continuous Glucose Monitoring System under Conditions Similar to Daily Life
doi:
Figure Lengend Snippet: Clarke EGA of the paired values obtained with a CGM system (Dexcom G4) and a reference measurement with a BG meter (ACCU-CHEK Aviva). Clinically accurate or acceptable readings are represented by dots in the zones A and B.
Article Snippet: According to the local distributor, the Dexcom G4 stand-alone system is identical to the
Techniques:
Journal: Journal of Diabetes Science and Technology
Article Title: Assessing the Accuracy of Continuous Glucose Monitoring (CGM) Calibrated With Capillary Values Using Capillary or Venous Glucose Levels as a Reference
doi: 10.1177/1932296815626724
Figure Lengend Snippet: Mean Absolute Relative Difference (MARD) of Dexcom G4 based on Capillary Versus Venous Glucose References When Calibrating CGM by Capillary Values.
Article Snippet: The purpose of the study was to compare the accuracy of a stand-alone
Techniques:
Journal: Journal of Diabetes Science and Technology
Article Title: Assessing the Accuracy of Continuous Glucose Monitoring (CGM) Calibrated With Capillary Values Using Capillary or Venous Glucose Levels as a Reference
doi: 10.1177/1932296815626724
Figure Lengend Snippet: MARD for Dexcom G4 as a continuous function of capillary and venous glucose levels when calibrating CGM with capillary glucose values. Absolute relative difference (ARD) for Dexcom G4 in relation to capillary and venous glucose concentrations is also plotted for all observations in the cohort.
Article Snippet: The purpose of the study was to compare the accuracy of a stand-alone
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Summary of Included Studies
Article Snippet: Daily and Annual Costs of Diabetes Treatment Supplies a Table A14:
Techniques: Biomarker Discovery, Control, Injection
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Disease Interventions and Comparators Evaluated in the Primary Economic Model
Article Snippet: Daily and Annual Costs of Diabetes Treatment Supplies a Table A14:
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Mean A1C Levels, Changes From Baseline With Continuous Glucose Monitoring a
Article Snippet: Daily and Annual Costs of Diabetes Treatment Supplies a Table A14:
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Change in A1C From Baseline and Risk Reduction for Diabetes Complications
Article Snippet: Daily and Annual Costs of Diabetes Treatment Supplies a Table A14:
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Average Annual Per-Patient Cost of Diabetes Complications and Interventions in Ontario
Article Snippet: Daily and Annual Costs of Diabetes Treatment Supplies a Table A14:
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Daily and Annual Costs of Diabetes Treatment Supplies a
Article Snippet: Daily and Annual Costs of Diabetes Treatment Supplies a Table A14:
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Annual Costs of Continuous Glucose Monitoring and Insulin Pump a
Article Snippet: Daily and Annual Costs of Diabetes Treatment Supplies a Table A14:
Techniques: Battery
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Costs of Different Diabetes Treatment Technologies a
Article Snippet: Daily and Annual Costs of Diabetes Treatment Supplies a Table A14:
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Cost to Patient of Technologies With Various Levels of Government Funding
Article Snippet: Daily and Annual Costs of Diabetes Treatment Supplies a Table A14:
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Base Case Analysis
Article Snippet: Daily and Annual Costs of Diabetes Treatment Supplies a Table A14:
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Scenario 1 Results a
Article Snippet: Daily and Annual Costs of Diabetes Treatment Supplies a Table A14:
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Scenario 2 Results
Article Snippet: Daily and Annual Costs of Diabetes Treatment Supplies a Table A14:
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Scenario 3 Results
Article Snippet: Daily and Annual Costs of Diabetes Treatment Supplies a Table A14:
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Scenario 4 Results
Article Snippet: Daily and Annual Costs of Diabetes Treatment Supplies a Table A14:
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Scenario 5 Results
Article Snippet: Daily and Annual Costs of Diabetes Treatment Supplies a Table A14:
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Estimated Number of Current Users of Continuous Glucose Monitoring in Ontario by Age Group
Article Snippet: Daily and Annual Costs of Diabetes Treatment Supplies a Table A14:
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Estimated Annual Number of Patients Using Continuous Glucose Monitoring in Ontario, Manufacturer Projections
Article Snippet: Daily and Annual Costs of Diabetes Treatment Supplies a Table A14:
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Estimated Annual Number of Patients Using Continuous Glucose Monitoring in Ontario, Conservative Projections
Article Snippet: Daily and Annual Costs of Diabetes Treatment Supplies a Table A14:
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Estimated Annual Per-Patient Costs of Continuous Glucose Monitoring When Insulin Pump, Insulin, and Supplies Are Publicly Funded
Article Snippet: Daily and Annual Costs of Diabetes Treatment Supplies a Table A14:
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Estimated Annual Per-Patient Costs (All Direct Medical Costs) of Continuous Glucose Monitoring in Ontario
Article Snippet: Daily and Annual Costs of Diabetes Treatment Supplies a Table A14:
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Estimated Annual Per-Patient Costs of Continuous Glucose Monitoring when Insulin Pump, Insulin, and 75% of Sensor Costs Are Publicly Funded
Article Snippet: Daily and Annual Costs of Diabetes Treatment Supplies a Table A14:
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet:
Article Snippet: Daily and Annual Costs of Diabetes Treatment Supplies a Table A14:
Techniques: Control
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet:
Article Snippet: Daily and Annual Costs of Diabetes Treatment Supplies a Table A14:
Techniques: Control
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Reasons for Including Four Interventions in the Primary Economic Analysis
Article Snippet: Daily and Annual Costs of Diabetes Treatment Supplies a Table A14:
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Summary of Included Studies
Article Snippet: Daily and Annual Costs of Diabetes Treatment Supplies a table ft1 table-wrap mode="anchored" t5 Table A14:
Techniques: Biomarker Discovery, Control, Injection
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Disease Interventions and Comparators Evaluated in the Primary Economic Model
Article Snippet: Daily and Annual Costs of Diabetes Treatment Supplies a table ft1 table-wrap mode="anchored" t5 Table A14:
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Mean A1C Levels, Changes From Baseline With Continuous Glucose Monitoring a
Article Snippet: Daily and Annual Costs of Diabetes Treatment Supplies a table ft1 table-wrap mode="anchored" t5 Table A14:
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Change in A1C From Baseline and Risk Reduction for Diabetes Complications
Article Snippet: Daily and Annual Costs of Diabetes Treatment Supplies a table ft1 table-wrap mode="anchored" t5 Table A14:
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Average Annual Per-Patient Cost of Diabetes Complications and Interventions in Ontario
Article Snippet: Daily and Annual Costs of Diabetes Treatment Supplies a table ft1 table-wrap mode="anchored" t5 Table A14:
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Daily and Annual Costs of Diabetes Treatment Supplies a
Article Snippet: Daily and Annual Costs of Diabetes Treatment Supplies a table ft1 table-wrap mode="anchored" t5 Table A14:
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Annual Costs of Continuous Glucose Monitoring and Insulin Pump a
Article Snippet: Daily and Annual Costs of Diabetes Treatment Supplies a table ft1 table-wrap mode="anchored" t5 Table A14:
Techniques: Battery
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Costs of Different Diabetes Treatment Technologies a
Article Snippet: Daily and Annual Costs of Diabetes Treatment Supplies a table ft1 table-wrap mode="anchored" t5 Table A14:
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Cost to Patient of Technologies With Various Levels of Government Funding
Article Snippet: Daily and Annual Costs of Diabetes Treatment Supplies a table ft1 table-wrap mode="anchored" t5 Table A14:
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Base Case Analysis
Article Snippet: Daily and Annual Costs of Diabetes Treatment Supplies a table ft1 table-wrap mode="anchored" t5 Table A14:
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Scenario 1 Results a
Article Snippet: Daily and Annual Costs of Diabetes Treatment Supplies a table ft1 table-wrap mode="anchored" t5 Table A14:
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Scenario 2 Results
Article Snippet: Daily and Annual Costs of Diabetes Treatment Supplies a table ft1 table-wrap mode="anchored" t5 Table A14:
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Scenario 3 Results
Article Snippet: Daily and Annual Costs of Diabetes Treatment Supplies a table ft1 table-wrap mode="anchored" t5 Table A14:
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Scenario 4 Results
Article Snippet: Daily and Annual Costs of Diabetes Treatment Supplies a table ft1 table-wrap mode="anchored" t5 Table A14:
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Scenario 5 Results
Article Snippet: Daily and Annual Costs of Diabetes Treatment Supplies a table ft1 table-wrap mode="anchored" t5 Table A14:
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Estimated Number of Current Users of Continuous Glucose Monitoring in Ontario by Age Group
Article Snippet: Daily and Annual Costs of Diabetes Treatment Supplies a table ft1 table-wrap mode="anchored" t5 Table A14:
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Estimated Annual Number of Patients Using Continuous Glucose Monitoring in Ontario, Manufacturer Projections
Article Snippet: Daily and Annual Costs of Diabetes Treatment Supplies a table ft1 table-wrap mode="anchored" t5 Table A14:
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Estimated Annual Number of Patients Using Continuous Glucose Monitoring in Ontario, Conservative Projections
Article Snippet: Daily and Annual Costs of Diabetes Treatment Supplies a table ft1 table-wrap mode="anchored" t5 Table A14:
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Estimated Annual Per-Patient Costs of Continuous Glucose Monitoring When Insulin Pump, Insulin, and Supplies Are Publicly Funded
Article Snippet: Daily and Annual Costs of Diabetes Treatment Supplies a table ft1 table-wrap mode="anchored" t5 Table A14:
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Estimated Annual Per-Patient Costs (All Direct Medical Costs) of Continuous Glucose Monitoring in Ontario
Article Snippet: Daily and Annual Costs of Diabetes Treatment Supplies a table ft1 table-wrap mode="anchored" t5 Table A14:
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Estimated Annual Per-Patient Costs of Continuous Glucose Monitoring when Insulin Pump, Insulin, and 75% of Sensor Costs Are Publicly Funded
Article Snippet: Daily and Annual Costs of Diabetes Treatment Supplies a table ft1 table-wrap mode="anchored" t5 Table A14:
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet:
Article Snippet: Daily and Annual Costs of Diabetes Treatment Supplies a table ft1 table-wrap mode="anchored" t5 Table A14:
Techniques: Control
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet:
Article Snippet: Daily and Annual Costs of Diabetes Treatment Supplies a table ft1 table-wrap mode="anchored" t5 Table A14:
Techniques: Control
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Reasons for Including Four Interventions in the Primary Economic Analysis
Article Snippet: Daily and Annual Costs of Diabetes Treatment Supplies a table ft1 table-wrap mode="anchored" t5 Table A14:
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Disease Interventions and Comparators Evaluated in the Primary Economic Model
Article Snippet: 14 There was no direct evidence that continuous glucose monitoring prevented hospitalizations owing to hypoglycemic events, 25 , 33 , 39 so we did not consider this possibility in our model. table ft1 table-wrap mode="anchored" t5 Table 18: caption a7 Mean Cost ($) a Source First Year Subsequent Years Health State: Diabetes-Related Complications Nephropathy 80 13 O'Brien et al 2003 95 Neuropathy 192 192 O'Brien et al 2003 95 Retinopathy 492 52 O'Brien et al 2003 95 Severe hypoglycemic event (in-patient visit) 3,775 3,775 McQueen et al, 2015 97 Cardiovascular disease 18,682 4,072 O'Reilly et al, 2007 96 Blindness 3,483 2,482 O'Reilly et al, 2007 96 Lower-extremity amputation 43,984 6,024 O'Reilly et al, 2007 96 End-stage renal disease 28,221 12,808 O'Reilly et al, 2007 96 Intervention (Trade Name) Sensor-augmented pump (Dexcom G4 Platinum + Animas Vibe) 11,811 11,811 Dexcom and Animas b Sensor-augmented pump (Dexcom G5 Mobile + Animas Vibe) 11,534 11,534 Dexcom and Animas b Sensor-augmented pump with a low-glucose suspend feature (MiniMed Veo) 9,211 9,211
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Mean A1C Levels, Changes From Baseline With Continuous Glucose Monitoring a
Article Snippet: 14 There was no direct evidence that continuous glucose monitoring prevented hospitalizations owing to hypoglycemic events, 25 , 33 , 39 so we did not consider this possibility in our model. table ft1 table-wrap mode="anchored" t5 Table 18: caption a7 Mean Cost ($) a Source First Year Subsequent Years Health State: Diabetes-Related Complications Nephropathy 80 13 O'Brien et al 2003 95 Neuropathy 192 192 O'Brien et al 2003 95 Retinopathy 492 52 O'Brien et al 2003 95 Severe hypoglycemic event (in-patient visit) 3,775 3,775 McQueen et al, 2015 97 Cardiovascular disease 18,682 4,072 O'Reilly et al, 2007 96 Blindness 3,483 2,482 O'Reilly et al, 2007 96 Lower-extremity amputation 43,984 6,024 O'Reilly et al, 2007 96 End-stage renal disease 28,221 12,808 O'Reilly et al, 2007 96 Intervention (Trade Name) Sensor-augmented pump (Dexcom G4 Platinum + Animas Vibe) 11,811 11,811 Dexcom and Animas b Sensor-augmented pump (Dexcom G5 Mobile + Animas Vibe) 11,534 11,534 Dexcom and Animas b Sensor-augmented pump with a low-glucose suspend feature (MiniMed Veo) 9,211 9,211
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Change in A1C From Baseline and Risk Reduction for Diabetes Complications
Article Snippet: 14 There was no direct evidence that continuous glucose monitoring prevented hospitalizations owing to hypoglycemic events, 25 , 33 , 39 so we did not consider this possibility in our model. table ft1 table-wrap mode="anchored" t5 Table 18: caption a7 Mean Cost ($) a Source First Year Subsequent Years Health State: Diabetes-Related Complications Nephropathy 80 13 O'Brien et al 2003 95 Neuropathy 192 192 O'Brien et al 2003 95 Retinopathy 492 52 O'Brien et al 2003 95 Severe hypoglycemic event (in-patient visit) 3,775 3,775 McQueen et al, 2015 97 Cardiovascular disease 18,682 4,072 O'Reilly et al, 2007 96 Blindness 3,483 2,482 O'Reilly et al, 2007 96 Lower-extremity amputation 43,984 6,024 O'Reilly et al, 2007 96 End-stage renal disease 28,221 12,808 O'Reilly et al, 2007 96 Intervention (Trade Name) Sensor-augmented pump (Dexcom G4 Platinum + Animas Vibe) 11,811 11,811 Dexcom and Animas b Sensor-augmented pump (Dexcom G5 Mobile + Animas Vibe) 11,534 11,534 Dexcom and Animas b Sensor-augmented pump with a low-glucose suspend feature (MiniMed Veo) 9,211 9,211
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Average Annual Per-Patient Cost of Diabetes Complications and Interventions in Ontario
Article Snippet: 14 There was no direct evidence that continuous glucose monitoring prevented hospitalizations owing to hypoglycemic events, 25 , 33 , 39 so we did not consider this possibility in our model. table ft1 table-wrap mode="anchored" t5 Table 18: caption a7 Mean Cost ($) a Source First Year Subsequent Years Health State: Diabetes-Related Complications Nephropathy 80 13 O'Brien et al 2003 95 Neuropathy 192 192 O'Brien et al 2003 95 Retinopathy 492 52 O'Brien et al 2003 95 Severe hypoglycemic event (in-patient visit) 3,775 3,775 McQueen et al, 2015 97 Cardiovascular disease 18,682 4,072 O'Reilly et al, 2007 96 Blindness 3,483 2,482 O'Reilly et al, 2007 96 Lower-extremity amputation 43,984 6,024 O'Reilly et al, 2007 96 End-stage renal disease 28,221 12,808 O'Reilly et al, 2007 96 Intervention (Trade Name) Sensor-augmented pump (Dexcom G4 Platinum + Animas Vibe) 11,811 11,811 Dexcom and Animas b Sensor-augmented pump (Dexcom G5 Mobile + Animas Vibe) 11,534 11,534 Dexcom and Animas b Sensor-augmented pump with a low-glucose suspend feature (MiniMed Veo) 9,211 9,211
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Daily and Annual Costs of Diabetes Treatment Supplies a
Article Snippet: 14 There was no direct evidence that continuous glucose monitoring prevented hospitalizations owing to hypoglycemic events, 25 , 33 , 39 so we did not consider this possibility in our model. table ft1 table-wrap mode="anchored" t5 Table 18: caption a7 Mean Cost ($) a Source First Year Subsequent Years Health State: Diabetes-Related Complications Nephropathy 80 13 O'Brien et al 2003 95 Neuropathy 192 192 O'Brien et al 2003 95 Retinopathy 492 52 O'Brien et al 2003 95 Severe hypoglycemic event (in-patient visit) 3,775 3,775 McQueen et al, 2015 97 Cardiovascular disease 18,682 4,072 O'Reilly et al, 2007 96 Blindness 3,483 2,482 O'Reilly et al, 2007 96 Lower-extremity amputation 43,984 6,024 O'Reilly et al, 2007 96 End-stage renal disease 28,221 12,808 O'Reilly et al, 2007 96 Intervention (Trade Name) Sensor-augmented pump (Dexcom G4 Platinum + Animas Vibe) 11,811 11,811 Dexcom and Animas b Sensor-augmented pump (Dexcom G5 Mobile + Animas Vibe) 11,534 11,534 Dexcom and Animas b Sensor-augmented pump with a low-glucose suspend feature (MiniMed Veo) 9,211 9,211
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Annual Costs of Continuous Glucose Monitoring and Insulin Pump a
Article Snippet: 14 There was no direct evidence that continuous glucose monitoring prevented hospitalizations owing to hypoglycemic events, 25 , 33 , 39 so we did not consider this possibility in our model. table ft1 table-wrap mode="anchored" t5 Table 18: caption a7 Mean Cost ($) a Source First Year Subsequent Years Health State: Diabetes-Related Complications Nephropathy 80 13 O'Brien et al 2003 95 Neuropathy 192 192 O'Brien et al 2003 95 Retinopathy 492 52 O'Brien et al 2003 95 Severe hypoglycemic event (in-patient visit) 3,775 3,775 McQueen et al, 2015 97 Cardiovascular disease 18,682 4,072 O'Reilly et al, 2007 96 Blindness 3,483 2,482 O'Reilly et al, 2007 96 Lower-extremity amputation 43,984 6,024 O'Reilly et al, 2007 96 End-stage renal disease 28,221 12,808 O'Reilly et al, 2007 96 Intervention (Trade Name) Sensor-augmented pump (Dexcom G4 Platinum + Animas Vibe) 11,811 11,811 Dexcom and Animas b Sensor-augmented pump (Dexcom G5 Mobile + Animas Vibe) 11,534 11,534 Dexcom and Animas b Sensor-augmented pump with a low-glucose suspend feature (MiniMed Veo) 9,211 9,211
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Cost to Patient of Technologies With Various Levels of Government Funding
Article Snippet: 14 There was no direct evidence that continuous glucose monitoring prevented hospitalizations owing to hypoglycemic events, 25 , 33 , 39 so we did not consider this possibility in our model. table ft1 table-wrap mode="anchored" t5 Table 18: caption a7 Mean Cost ($) a Source First Year Subsequent Years Health State: Diabetes-Related Complications Nephropathy 80 13 O'Brien et al 2003 95 Neuropathy 192 192 O'Brien et al 2003 95 Retinopathy 492 52 O'Brien et al 2003 95 Severe hypoglycemic event (in-patient visit) 3,775 3,775 McQueen et al, 2015 97 Cardiovascular disease 18,682 4,072 O'Reilly et al, 2007 96 Blindness 3,483 2,482 O'Reilly et al, 2007 96 Lower-extremity amputation 43,984 6,024 O'Reilly et al, 2007 96 End-stage renal disease 28,221 12,808 O'Reilly et al, 2007 96 Intervention (Trade Name) Sensor-augmented pump (Dexcom G4 Platinum + Animas Vibe) 11,811 11,811 Dexcom and Animas b Sensor-augmented pump (Dexcom G5 Mobile + Animas Vibe) 11,534 11,534 Dexcom and Animas b Sensor-augmented pump with a low-glucose suspend feature (MiniMed Veo) 9,211 9,211
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Base Case Analysis
Article Snippet: 14 There was no direct evidence that continuous glucose monitoring prevented hospitalizations owing to hypoglycemic events, 25 , 33 , 39 so we did not consider this possibility in our model. table ft1 table-wrap mode="anchored" t5 Table 18: caption a7 Mean Cost ($) a Source First Year Subsequent Years Health State: Diabetes-Related Complications Nephropathy 80 13 O'Brien et al 2003 95 Neuropathy 192 192 O'Brien et al 2003 95 Retinopathy 492 52 O'Brien et al 2003 95 Severe hypoglycemic event (in-patient visit) 3,775 3,775 McQueen et al, 2015 97 Cardiovascular disease 18,682 4,072 O'Reilly et al, 2007 96 Blindness 3,483 2,482 O'Reilly et al, 2007 96 Lower-extremity amputation 43,984 6,024 O'Reilly et al, 2007 96 End-stage renal disease 28,221 12,808 O'Reilly et al, 2007 96 Intervention (Trade Name) Sensor-augmented pump (Dexcom G4 Platinum + Animas Vibe) 11,811 11,811 Dexcom and Animas b Sensor-augmented pump (Dexcom G5 Mobile + Animas Vibe) 11,534 11,534 Dexcom and Animas b Sensor-augmented pump with a low-glucose suspend feature (MiniMed Veo) 9,211 9,211
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Scenario 1 Results a
Article Snippet: 14 There was no direct evidence that continuous glucose monitoring prevented hospitalizations owing to hypoglycemic events, 25 , 33 , 39 so we did not consider this possibility in our model. table ft1 table-wrap mode="anchored" t5 Table 18: caption a7 Mean Cost ($) a Source First Year Subsequent Years Health State: Diabetes-Related Complications Nephropathy 80 13 O'Brien et al 2003 95 Neuropathy 192 192 O'Brien et al 2003 95 Retinopathy 492 52 O'Brien et al 2003 95 Severe hypoglycemic event (in-patient visit) 3,775 3,775 McQueen et al, 2015 97 Cardiovascular disease 18,682 4,072 O'Reilly et al, 2007 96 Blindness 3,483 2,482 O'Reilly et al, 2007 96 Lower-extremity amputation 43,984 6,024 O'Reilly et al, 2007 96 End-stage renal disease 28,221 12,808 O'Reilly et al, 2007 96 Intervention (Trade Name) Sensor-augmented pump (Dexcom G4 Platinum + Animas Vibe) 11,811 11,811 Dexcom and Animas b Sensor-augmented pump (Dexcom G5 Mobile + Animas Vibe) 11,534 11,534 Dexcom and Animas b Sensor-augmented pump with a low-glucose suspend feature (MiniMed Veo) 9,211 9,211
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Scenario 2 Results
Article Snippet: 14 There was no direct evidence that continuous glucose monitoring prevented hospitalizations owing to hypoglycemic events, 25 , 33 , 39 so we did not consider this possibility in our model. table ft1 table-wrap mode="anchored" t5 Table 18: caption a7 Mean Cost ($) a Source First Year Subsequent Years Health State: Diabetes-Related Complications Nephropathy 80 13 O'Brien et al 2003 95 Neuropathy 192 192 O'Brien et al 2003 95 Retinopathy 492 52 O'Brien et al 2003 95 Severe hypoglycemic event (in-patient visit) 3,775 3,775 McQueen et al, 2015 97 Cardiovascular disease 18,682 4,072 O'Reilly et al, 2007 96 Blindness 3,483 2,482 O'Reilly et al, 2007 96 Lower-extremity amputation 43,984 6,024 O'Reilly et al, 2007 96 End-stage renal disease 28,221 12,808 O'Reilly et al, 2007 96 Intervention (Trade Name) Sensor-augmented pump (Dexcom G4 Platinum + Animas Vibe) 11,811 11,811 Dexcom and Animas b Sensor-augmented pump (Dexcom G5 Mobile + Animas Vibe) 11,534 11,534 Dexcom and Animas b Sensor-augmented pump with a low-glucose suspend feature (MiniMed Veo) 9,211 9,211
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Scenario 3 Results
Article Snippet: 14 There was no direct evidence that continuous glucose monitoring prevented hospitalizations owing to hypoglycemic events, 25 , 33 , 39 so we did not consider this possibility in our model. table ft1 table-wrap mode="anchored" t5 Table 18: caption a7 Mean Cost ($) a Source First Year Subsequent Years Health State: Diabetes-Related Complications Nephropathy 80 13 O'Brien et al 2003 95 Neuropathy 192 192 O'Brien et al 2003 95 Retinopathy 492 52 O'Brien et al 2003 95 Severe hypoglycemic event (in-patient visit) 3,775 3,775 McQueen et al, 2015 97 Cardiovascular disease 18,682 4,072 O'Reilly et al, 2007 96 Blindness 3,483 2,482 O'Reilly et al, 2007 96 Lower-extremity amputation 43,984 6,024 O'Reilly et al, 2007 96 End-stage renal disease 28,221 12,808 O'Reilly et al, 2007 96 Intervention (Trade Name) Sensor-augmented pump (Dexcom G4 Platinum + Animas Vibe) 11,811 11,811 Dexcom and Animas b Sensor-augmented pump (Dexcom G5 Mobile + Animas Vibe) 11,534 11,534 Dexcom and Animas b Sensor-augmented pump with a low-glucose suspend feature (MiniMed Veo) 9,211 9,211
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Scenario 4 Results
Article Snippet: 14 There was no direct evidence that continuous glucose monitoring prevented hospitalizations owing to hypoglycemic events, 25 , 33 , 39 so we did not consider this possibility in our model. table ft1 table-wrap mode="anchored" t5 Table 18: caption a7 Mean Cost ($) a Source First Year Subsequent Years Health State: Diabetes-Related Complications Nephropathy 80 13 O'Brien et al 2003 95 Neuropathy 192 192 O'Brien et al 2003 95 Retinopathy 492 52 O'Brien et al 2003 95 Severe hypoglycemic event (in-patient visit) 3,775 3,775 McQueen et al, 2015 97 Cardiovascular disease 18,682 4,072 O'Reilly et al, 2007 96 Blindness 3,483 2,482 O'Reilly et al, 2007 96 Lower-extremity amputation 43,984 6,024 O'Reilly et al, 2007 96 End-stage renal disease 28,221 12,808 O'Reilly et al, 2007 96 Intervention (Trade Name) Sensor-augmented pump (Dexcom G4 Platinum + Animas Vibe) 11,811 11,811 Dexcom and Animas b Sensor-augmented pump (Dexcom G5 Mobile + Animas Vibe) 11,534 11,534 Dexcom and Animas b Sensor-augmented pump with a low-glucose suspend feature (MiniMed Veo) 9,211 9,211
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Scenario 5 Results
Article Snippet: 14 There was no direct evidence that continuous glucose monitoring prevented hospitalizations owing to hypoglycemic events, 25 , 33 , 39 so we did not consider this possibility in our model. table ft1 table-wrap mode="anchored" t5 Table 18: caption a7 Mean Cost ($) a Source First Year Subsequent Years Health State: Diabetes-Related Complications Nephropathy 80 13 O'Brien et al 2003 95 Neuropathy 192 192 O'Brien et al 2003 95 Retinopathy 492 52 O'Brien et al 2003 95 Severe hypoglycemic event (in-patient visit) 3,775 3,775 McQueen et al, 2015 97 Cardiovascular disease 18,682 4,072 O'Reilly et al, 2007 96 Blindness 3,483 2,482 O'Reilly et al, 2007 96 Lower-extremity amputation 43,984 6,024 O'Reilly et al, 2007 96 End-stage renal disease 28,221 12,808 O'Reilly et al, 2007 96 Intervention (Trade Name) Sensor-augmented pump (Dexcom G4 Platinum + Animas Vibe) 11,811 11,811 Dexcom and Animas b Sensor-augmented pump (Dexcom G5 Mobile + Animas Vibe) 11,534 11,534 Dexcom and Animas b Sensor-augmented pump with a low-glucose suspend feature (MiniMed Veo) 9,211 9,211
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Estimated Number of Current Users of Continuous Glucose Monitoring in Ontario by Age Group
Article Snippet: 14 There was no direct evidence that continuous glucose monitoring prevented hospitalizations owing to hypoglycemic events, 25 , 33 , 39 so we did not consider this possibility in our model. table ft1 table-wrap mode="anchored" t5 Table 18: caption a7 Mean Cost ($) a Source First Year Subsequent Years Health State: Diabetes-Related Complications Nephropathy 80 13 O'Brien et al 2003 95 Neuropathy 192 192 O'Brien et al 2003 95 Retinopathy 492 52 O'Brien et al 2003 95 Severe hypoglycemic event (in-patient visit) 3,775 3,775 McQueen et al, 2015 97 Cardiovascular disease 18,682 4,072 O'Reilly et al, 2007 96 Blindness 3,483 2,482 O'Reilly et al, 2007 96 Lower-extremity amputation 43,984 6,024 O'Reilly et al, 2007 96 End-stage renal disease 28,221 12,808 O'Reilly et al, 2007 96 Intervention (Trade Name) Sensor-augmented pump (Dexcom G4 Platinum + Animas Vibe) 11,811 11,811 Dexcom and Animas b Sensor-augmented pump (Dexcom G5 Mobile + Animas Vibe) 11,534 11,534 Dexcom and Animas b Sensor-augmented pump with a low-glucose suspend feature (MiniMed Veo) 9,211 9,211
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Estimated Annual Number of Patients Using Continuous Glucose Monitoring in Ontario, Manufacturer Projections
Article Snippet: 14 There was no direct evidence that continuous glucose monitoring prevented hospitalizations owing to hypoglycemic events, 25 , 33 , 39 so we did not consider this possibility in our model. table ft1 table-wrap mode="anchored" t5 Table 18: caption a7 Mean Cost ($) a Source First Year Subsequent Years Health State: Diabetes-Related Complications Nephropathy 80 13 O'Brien et al 2003 95 Neuropathy 192 192 O'Brien et al 2003 95 Retinopathy 492 52 O'Brien et al 2003 95 Severe hypoglycemic event (in-patient visit) 3,775 3,775 McQueen et al, 2015 97 Cardiovascular disease 18,682 4,072 O'Reilly et al, 2007 96 Blindness 3,483 2,482 O'Reilly et al, 2007 96 Lower-extremity amputation 43,984 6,024 O'Reilly et al, 2007 96 End-stage renal disease 28,221 12,808 O'Reilly et al, 2007 96 Intervention (Trade Name) Sensor-augmented pump (Dexcom G4 Platinum + Animas Vibe) 11,811 11,811 Dexcom and Animas b Sensor-augmented pump (Dexcom G5 Mobile + Animas Vibe) 11,534 11,534 Dexcom and Animas b Sensor-augmented pump with a low-glucose suspend feature (MiniMed Veo) 9,211 9,211
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Estimated Annual Number of Patients Using Continuous Glucose Monitoring in Ontario, Conservative Projections
Article Snippet: 14 There was no direct evidence that continuous glucose monitoring prevented hospitalizations owing to hypoglycemic events, 25 , 33 , 39 so we did not consider this possibility in our model. table ft1 table-wrap mode="anchored" t5 Table 18: caption a7 Mean Cost ($) a Source First Year Subsequent Years Health State: Diabetes-Related Complications Nephropathy 80 13 O'Brien et al 2003 95 Neuropathy 192 192 O'Brien et al 2003 95 Retinopathy 492 52 O'Brien et al 2003 95 Severe hypoglycemic event (in-patient visit) 3,775 3,775 McQueen et al, 2015 97 Cardiovascular disease 18,682 4,072 O'Reilly et al, 2007 96 Blindness 3,483 2,482 O'Reilly et al, 2007 96 Lower-extremity amputation 43,984 6,024 O'Reilly et al, 2007 96 End-stage renal disease 28,221 12,808 O'Reilly et al, 2007 96 Intervention (Trade Name) Sensor-augmented pump (Dexcom G4 Platinum + Animas Vibe) 11,811 11,811 Dexcom and Animas b Sensor-augmented pump (Dexcom G5 Mobile + Animas Vibe) 11,534 11,534 Dexcom and Animas b Sensor-augmented pump with a low-glucose suspend feature (MiniMed Veo) 9,211 9,211
Techniques:
Journal: Journal of Diabetes Science and Technology
Article Title: Performance Evaluation of a Continuous Glucose Monitoring System under Conditions Similar to Daily Life
doi:
Figure Lengend Snippet: Mean Absolute Relative Difference and Precision Absolute Relative Difference of the Dexcom G4 CGM System (Mean ± Standard Deviation) a
Article Snippet: According to the local distributor, the
Techniques: Standard Deviation
Journal: Journal of Diabetes Science and Technology
Article Title: Performance Evaluation of a Continuous Glucose Monitoring System under Conditions Similar to Daily Life
doi:
Figure Lengend Snippet: Clarke EGA of the paired values obtained with a CGM system (Dexcom G4) and a reference measurement with a BG meter (ACCU-CHEK Aviva). Clinically accurate or acceptable readings are represented by dots in the zones A and B.
Article Snippet: According to the local distributor, the
Techniques:
Journal: Journal of Diabetes Science and Technology
Article Title: Assessing the Accuracy of Continuous Glucose Monitoring (CGM) Calibrated With Capillary Values Using Capillary or Venous Glucose Levels as a Reference
doi: 10.1177/1932296815626724
Figure Lengend Snippet: Mean Absolute Relative Difference (MARD) of Dexcom G4 based on Capillary Versus Venous Glucose References When Calibrating CGM by Capillary Values.
Article Snippet: The
Techniques:
Journal: Journal of Diabetes Science and Technology
Article Title: Assessing the Accuracy of Continuous Glucose Monitoring (CGM) Calibrated With Capillary Values Using Capillary or Venous Glucose Levels as a Reference
doi: 10.1177/1932296815626724
Figure Lengend Snippet: MARD for Dexcom G4 as a continuous function of capillary and venous glucose levels when calibrating CGM with capillary glucose values. Absolute relative difference (ARD) for Dexcom G4 in relation to capillary and venous glucose concentrations is also plotted for all observations in the cohort.
Article Snippet: The
Techniques:
Journal: Journal of Diabetes Science and Technology
Article Title: Assessing the Accuracy of Continuous Glucose Monitoring (CGM) Calibrated With Capillary Values Using Capillary or Venous Glucose Levels as a Reference
doi: 10.1177/1932296815626724
Figure Lengend Snippet: Mean Absolute Relative Difference (MARD) of Dexcom G4 Based on Capillary Versus Venous Glucose References for Various Rates of Change.
Article Snippet: The
Techniques:
Journal: Diabetes Spectrum : A Publication of the American Diabetes Association
Article Title: Flash Continuous Glucose Monitoring: Implications for Use of Continuous Data in Daily Diabetes Management
doi: 10.2337/ds18-0059
Figure Lengend Snippet: Features of Selected CGM Systems ( 45 – 47 )
Article Snippet: Dexcom Platinum G4/G5 sensor with G4 Platinum transmitter , Up to 7 days , 2 hours , Every 12 hours , Every 5 minutes , 9% when used with most current Dexcom software , Stand alone with
Techniques: Software
Journal: Journal of Diabetes Science and Technology
Article Title: Performance Evaluation of a Continuous Glucose Monitoring System under Conditions Similar to Daily Life
doi:
Figure Lengend Snippet: Cumulative Percentage of Continuous Glucose Monitoring Readings within 5%, 10%, 20%, and 30% Deviation of Capillary Blood Glucose Readings a
Article Snippet:
Techniques:
Journal: Diabetes Spectrum : A Publication of the American Diabetes Association
Article Title: Flash Continuous Glucose Monitoring: Implications for Use of Continuous Data in Daily Diabetes Management
doi: 10.2337/ds18-0059
Figure Lengend Snippet: Features of Selected CGM Systems ( 45 – 47 )
Article Snippet:
Techniques: Software